DNASE1L3 and systemic lupus erythematosus: Interestingly, the principal component analysis (PCA) projection of disease activity, blood transcription modules (M1.2, M3.4, M5.12, M.5.15, and M7.16) and neutrophil count, showed that anti-DNase1L3 antibodies identify a subset of SLE patients with higher disease activity, neutrophil count and IFN/myeloid activation (Fig. 3d), which is also characterized by positivity for anti-dsDNA antibodies (Fig. 3f).